Log In
BCIQ
Print this Print this
 

grazoprevir (MK-5172)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral HCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotypes 1, 2 and 3 infection; Treat HCV genotype 1 infection in non-cirrhotic, treatment-naïve patients; Treat HCV genotype 1 infection in non-cirrhotic, treatment-naïve patients with an IL-28 CC genotype; Treat HCV genotype 1 infection in treatment-naïve patients; Treat non-cirrhotic treatment-naïve patients with HCV genotype 2, 4, 5 and 6 infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/29/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today